Skip to main content

Table 1 Satisfaction questionnaires results at 3 and 12- months assessment among the two groups (n = 60 at 3 months, n = 47 at 12 months)

From: Can a 3 months treatment with oral Desogestrel prior to insertion of the etonogestrel-releasing contraceptive implant improve continuation rate at 1 year? A randomized trial

Variable

3 M

P value

12 M

P value

ENG-Implant

DSG + ENG-Implant

ENG-Implant

DSG + ENG-Implant

Total

23

37

 

18

29

 

Weight gain

  

0.181

  

0.571

 No

13 (59.1)

28 (75.7)

 

10 (58.8)

13 (50.0)

 

 Yes

9 (40.9)

9 (24.3)

 

7 (41.2)

13 (50.0)

 

 Weight gain (kg), mean ± sd

1.1 ± 1.2

0.8 ± 1.4

0.209

3.1 ± 3.4

3.5 ± 3.1

0.704

Headache

  

0.724

  

0.711

 Never or rarely

15 (65.2)

24 (64.8)

 

15 (83.3)

22 (78.6)

 

 Often to frequently

8 (34.8)

12 (32.4)

 

3 (16.7)

5 (17.8)

 

 All the time

0

1 (2.7)

 

0

1 (3.6)

 

Acne

  

0.538

  

0.516

 Never or rarely

12 (54.5)

23 (62.2)

 

15 (83.3)

22 (75.9)

 

 Often to frequently

7 (31.8)

12 (32.4)

 

3 (16.7)

5 (17.2)

 

 All the time

3 (13.7)

2 (5.4)

 

0

2 (6.9)

 

Abdominal pain/bloating

  

0.378

  

0.543

 Never or rarely

12 (52.2)

22 (59.5)

 

15 (83.3)

22 (75.9)

 

 Often to frequently

11 (47.8)

13 (35.1)

 

3 (16.7)

7 (24.1)

 

 All the time

0

2 (5.4)

 

0

0

 

Mastodynia

  

0.191

  

0.180

 Never or rarely

21 (91.3)

29 (78.4)

 

16 (88.9)

21 (72.4)

 

 Often to frequently

2 (8.7)

8 (21.6)

 

2 (11.1)

8 (27.6)

 

 All the time

0

0

 

0

0

 

Vaginal infection

  

0.793

  

0.843

 Never or rarely

20 (87.0)

33 (89.2)

 

15 (83.3)

25 (89.3)

 

 Often to frequently

3 (13.0)

4 (10.8)

 

2 (11.1)

2 (7.1)

 

 All the time

0

0

 

1 (5.6)

1 (3.6)

 

Mood Swings

  

0.552

  

0.253

 Never or rarely

10 (43.5)

21 (56.8)

 

12 (66.7)

16 (55.2)

 

 Often to frequently

12 (52.2)

14 (37.8)

 

6 (33.3)

9 (31.0)

 

 All the time

1 (4.3)

2 (5.4)

 

0

4 (13.8)

 

Reduced sex drive

  

0.718

  

0.842

 Never or rarely

14 (60.9)

25 (69.4)

 

11 (61.1)

20 (69.0)

 

 Often to frequently

8 (34.8)

9 (25.0)

 

6 (33.3)

8 (27.6)

 

 All the time

1 (4.3)

2 (5.6)

 

1 (5.6)

1 (3.4)

 

Irregular vaginal bleeding

  

0.744

  

0.782

 Never or rarely

7 (30.4)

13 (35.1)

 

8 (44.4)

10 (34.5)

 

 Often to frequently

9 (39.1)

16 (43.2)

 

6 (33.3)

12 (41.4)

 

 All the time

7 (30.4)

8 (21.6)

 

4 (22.2)

7 (24.1)

 

 Discomfort with irregular vaginal bleeding

(from 0 to 10), mean ± sd

5.2 ± 3.6

4.5 ± 3.4

0.455

3.2 ± 3.9

4.8 ± 3.7

0.182

 Overall tolerance

(from 0 to 10), mean ± sd

6.7 ± 3.2

7.5 ± 2.4

0.300

7.8 ± 2.5

6.8 ± 2.6

0.191

 Overall satisfaction

(from 0 to 10), mean ± sd

7.2 ± 3.0

6.8 ± 3.0

0.641

8.5 ± 1.7

6.6 ± 2.9

0.012

 Desire to continue the contraceptive method

20 (87.0)

29 (80.6)

0.523

16 (80.0)

21 (72.4)

0.544

  1. ENG-Implant Etonogestrel-releasing contraceptive implant; DSG + ENG-Implant Daily oral 75 µg of desogestrel (DSG) for 3 months prior to the insertion of ENG-Implant; SD  Standard Deviation; n  number; 3 M assessment at 3 months since the beginning of the study; 12 M  assessment at 12 months since ENG-Implant insertion